<DOC>
	<DOC>NCT02598999</DOC>
	<brief_summary>This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of a single ascending doses (SAD) and multiple ascending doses (MAD) of Hypothiocyanite (OSCN-), bovine lactoferrin (bLF) and their combination (ALX-009) in healthy male volunteers and patients suffering from cystic fibrosis.</brief_summary>
	<brief_title>First-in-man Dose Escalation Study of ALX-009 and Its Components in Healthy Men and Cystic Fibrosis Suffering Patients</brief_title>
	<detailed_description>Part I : SAD of OSCN- and bLF in healthy male volunteers (cohorts 1 to 3) - Part II : SAD and MAD of ALX-009 in healthy male volunteers (cohorts 4 and 5) - Part III : SAD and MAD of ALX-009 in patients suffering from cystic fibrosis (cohort 6)</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Hypothiocyanite ion</mesh_term>
	<criteria>Healthy male subject (Parts I and II only) or patient suffering from cystic fibrosis (Part III only), aged between 18 and 50 years inclusive Subject's Body Mass Index between 18 and 30 kg/mÂ² Subject with normal blood pressure, heart rate, ECG recording and laboratory parameters at the screening visit Subject having given a written informed consent prior to selection Subject covered by Health Insurance System and/ or in compliance with the recommendations of National Law in force relating to biomedical research Specific Inclusion Criteria for Part III: Females of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration / Female of nonchildbearing potential: either surgically sterilized or at least 1 year postmenopausal Subject in a stable state (no exacerbation for 1 month or prescription of antibiotic by intravenous route) Presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic or infectious disease Frequent headaches and/or migraines, recurrent nausea and/or vomiting Symptomatic hypotension Blood donation (including in the frame of a clinical trial) within 2 months before administration General anaesthesia within 3 months before administration Presence or history of drug hypersensitivity, or any allergic disease Medical history of reactions to cow's milk proteins Subject who can not be contacted in case of emergency History or presence of drug or alcohol abuse Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests Subject who, in the judgement of the Investigator, is likely to be noncompliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development. Specific noninclusion criteria for part III: Exacerbation in the last month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>